ReviewInternational journal of surgery case reports2025
Robotic subtotal gastrectomy with Hugo™ robotic-assisted surgery (RAS) system: first report on a case series.
Review in International journal of surgery case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current Status and Future Perspectives of Robotic Surgery for Esophagogastric Cancer in Asia.Annals of gastroenterological surgery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Robotic-assisted surgery (RAS) has increasingly gained interest in gastric cancer treatment due to its enhanced precision and vision. Hugo™ RAS is a novel system designed to improve accessibility and reduce costs. However, its use in oncologic upper gastrointestinal procedures is still scarcely documented. Presentation of case: We report four consecutive cases of subtotal gastrectomy with D2 lymphadenectomy performed using Hugo™ RAS at a single institution. Patients were selected following multidisciplinary evaluation and underwent full robotic procedures with standardized port placements. Intraoperative parameters, complications, and short-term oncologic outcomes were analyzed. Discussion: All procedures were completed successfully without conversion or major complications. Median docking and console times were within acceptable limits, though longer than traditional laparoscopy due to system learning curve and intraoperative frozen section use. Lymphadenectomy was adequate in all D2 cases with R0 resection achieved. No blood transfusions were needed. Postoperative complications included delayed gastric emptying and a duodenal stump leak. The system proved safe, and the procedural setup did not require modifications from laparoscopic standards. Conclusion: Subtotal gastrectomy with D2 lymphadenectomy using Hugo™ RAS is feasible and safe. The standardized setup and available instruments support oncologic adequacy without energy devices. Further studies are needed to validate long-term outcomes and assess comparative advantages over conventional approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.